Bliss GVS Pharma Limited
BLISSGVS · ISIN: INE416D01022
Bliss GVS Pharma Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE416D01022.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Bliss GVS Pharma Limited - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-1.95%
3M
+46.23%
6M
+146.03%
1Y
+345%
3Y CAGR
+100.8%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Bliss GVS Pharma Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-09-28 | BULK | 22,50,000 |
Frequently asked questions
What is Bliss GVS Pharma Limited's 1-year and 3-year return?
Bliss GVS Pharma Limited's 1-year price return is +345%. Its 3-year CAGR (annualized return) is +100.8%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Bliss GVS Pharma Limited's latest financial performance?
Bliss GVS Pharma Limited's trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹1,074 Cr, with a TTM profit after tax of ₹166 Cr and an EBITDA margin of 22.7%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹15.22, with a 5-year EPS growth rate of 15.89% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Bliss GVS Pharma Limited's quality score?
Bliss GVS Pharma Limited has a Punji quality score of 72.7 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Bliss GVS Pharma Limited's technical indicators show?
As of 2026-10-29, Bliss GVS Pharma Limited's RSI (14-day) is 56.97 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Bliss GVS Pharma Limited?
As of 2026-09-30, Bliss GVS Pharma Limited's shareholding is split across Promoter (50.07%), Public (49.93%). Promoter holding of 50.07% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Has Bliss GVS Pharma Limited seen any recent bulk or block deals?
Yes, as of 2026-09-28 - the most recent recorded deal was a BULK on 2026-09-28 for 22,50,000 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns